Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.32 |
| ▸ | HTR2C | P28335 | 3/20 | 0.32 |
| ▸ | HTR2B | P41595 | 3/20 | 0.32 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.31 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.31 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.31 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.31 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.31 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.31 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8648641 | 0.71 | TMEM97 (0.37) | HTR2AHTR2CHTR2BCHRM2CHRM4 | |
| SCHEMBL15265879 | 0.71 | CHRM2 (0.36) | HTR2AHTR2CHTR2BCHRM2CHRM4 | |
| SCHEMBL5331260 | 0.69 | TMEM97 (0.39) | HTR2AHTR2CHTR2BCHRM2CHRM4 | |
| SCHEMBL2287265 | 0.66 | GAA (0.36) | HTR2CHTR2B | |
| SCHEMBL29842453 | 0.66 | GAA (0.36) | HTR2CHTR2B | |
| SCHEMBL1387826 | 0.64 | GAA (0.36) | — | |
| SCHEMBL18573347 | 0.63 | GAA (0.33) | — | |
| SCHEMBL22584880 | 0.63 | GAA (0.33) | — | |
| SCHEMBL79022 | 0.63 | KDM4E (0.39) | — | |
| SCHEMBL251287 | 0.63 | KDM4E (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060069277-A1 | CHIRAL ORGANOMETALLIC COMPOUNDS FOR USE IN ASYMMETRIC SYNTHESIS | AVECIA LIMITED (GB) | 2006-03-30 | — | — | US | disclosed |
| US-7019158-B1 | Chiral organometallic compounds for use in asymmetric synthesis | AVECIA LIMITED (GB) | 2006-03-28 | — | — | US | disclosed |
| EP-1417030-A1 | CHIRAL ORGANOMETALLIC COMPOUNDS FOR USE IN ASYMMETRIC SYNTHESIS | Avecia Limited (GB) | 2004-05-12 | — | — | EP | disclosed |
| WO-2003013724-A1 | CHIRAL ORGANOMETALLIC COMPOUNDS FOR USE IN ASYMMETRIC SYNTHESIS | AVECIA LIMITED (GB) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069277-A1 | CHIRAL ORGANOMETALLIC COMPOUNDS FOR USE IN ASYMMETRIC SYNTHESIS | PIN1, PRMT7, PRMT5 | HTR2A 4631/4885HTR2C 4052/4885HTR2B 4145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.